- Home
- REAL vs ZBIO Comparison
REAL vs ZBIO Comparison
Compare REAL & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ZBIO
- Stock Information
- Founded
- REAL 2011
- ZBIO 2019
- Country
- REAL United States
- ZBIO United States
- Employees
- REAL N/A
- ZBIO N/A
- Industry
- REAL Other Specialty Stores
- ZBIO
- Sector
- REAL Consumer Discretionary
- ZBIO
- Exchange
- REAL Nasdaq
- ZBIO NYSE
- Market Cap
- REAL 639.0M
- ZBIO 682.7M
- IPO Year
- REAL 2019
- ZBIO 2024
- Fundamental
- Price
- REAL $5.24
- ZBIO $15.41
- Analyst Decision
- REAL Buy
- ZBIO Strong Buy
- Analyst Count
- REAL 6
- ZBIO 7
- Target Price
- REAL $8.33
- ZBIO $32.29
- AVG Volume (30 Days)
- REAL 2.4M
- ZBIO 150.3K
- Earning Date
- REAL 08-07-2025
- ZBIO 08-16-2025
- Dividend Yield
- REAL N/A
- ZBIO N/A
- EPS Growth
- REAL N/A
- ZBIO N/A
- EPS
- REAL N/A
- ZBIO N/A
- Revenue
- REAL $616,717,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- REAL $11.73
- ZBIO $165.20
- Revenue Next Year
- REAL $9.98
- ZBIO $63.75
- P/E Ratio
- REAL N/A
- ZBIO N/A
- Revenue Growth
- REAL 11.89
- ZBIO N/A
- 52 Week Low
- REAL $2.24
- ZBIO $5.83
- 52 Week High
- REAL $11.38
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- REAL 43.70
- ZBIO N/A
- Support Level
- REAL $5.17
- ZBIO N/A
- Resistance Level
- REAL $6.69
- ZBIO N/A
- Average True Range (ATR)
- REAL 0.34
- ZBIO 0.00
- MACD
- REAL -0.07
- ZBIO 0.00
- Stochastic Oscillator
- REAL 14.20
- ZBIO 0.00
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.